Document Detail


Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
MedLine Citation:
PMID:  15205096     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The authors studied the long-term clinical and hematological response to hydroxyurea (HU) therapy in young patients, with either S/beta-thalassemia (beta(thal)) (8 patients) or SS (6 patients). All patients with S/beta(thal) responded well to treatment. Longitudinal evaluation of Hb, HbF, and MCV showed a significant increase compared to baseline levels, but the pattern of HbF changes varied among patients. Changes in HbF and Hb correlated well with baseline HbF. Favorable clinical responses, as documented by decline in hospitalization days for vasoocclusive crisis and transfused units of packed red blood cells, were also noted. During treatment, 1 patient was diagnosed with Hodgkin's lymphoma and 2 patients developed bilateral avascular necrosis of the femoral head. HU seems to be effective in a high proportion of young patients with sickle cell disease and in particular with S/beta(thal), but cannot eliminate occurrence of serious adverse events.
Authors:
Antonis Kattamis; Evangelia Lagona; Irini Orfanou; Fotini Psichou; Vasilis Ladis; Emmanuel Kanavakis; Anna Metaxotou-Mavrommati; Christos Kattamis
Related Documents :
20347396 - Association between duffy antigen receptor for chemokines expression and levels of infl...
8948666 - Factitious sickle cell acute painful episodes: a secondary type of munchausen syndrome.
7976626 - The effect of blood volume replacement on the mortality of head-injured patient.
1765296 - Relationship between peripheral vascular closure and proliferative retinopathy in sickl...
11930656 - Usefulness of determining a protein induced by vitamin k absence in detection of hepato...
6851466 - Use of vitamin e for prevention and treatment of spinocerebellar disorders.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pediatric hematology and oncology     Volume:  21     ISSN:  0888-0018     ISO Abbreviation:  Pediatr Hematol Oncol     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-06-18     Completed Date:  2005-03-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8700164     Medline TA:  Pediatr Hematol Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  335-42     Citation Subset:  IM    
Affiliation:
First Department of Pediatrics, University of Athens School of Medicine, Athens, Greece. ankatt@med.uoa.gr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Anemia, Sickle Cell / complications*,  drug therapy*
Child
Erythrocyte Indices
Erythrocyte Transfusion
Female
Fetal Hemoglobin / analysis
Hematologic Tests
Hemoglobins / analysis
Humans
Hydroxyurea / administration & dosage*
Length of Stay
Longitudinal Studies
Male
Thalassemia / drug therapy
Treatment Outcome
Chemical
Reg. No./Substance:
0/Hemoglobins; 127-07-1/Hydroxyurea; 9034-63-3/Fetal Hemoglobin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increased fetal iron load in rhesus hemolytic disease.
Next Document:  Metamizole sodium-induced severe aplastic anemia and its recovery with a short-course steroid therap...